Gainers
- Serina Therapeutics SER shares moved upwards by 33.8% to $6.69 during Thursday's pre-market session. The market value of their outstanding shares is at $59.4 million. As per the press release, Q3 earnings came out 2 days ago.
- Tivic Health Systems TIVC shares moved upwards by 18.3% to $0.39. The company's market cap stands at $2.4 million. As per the press release, Q3 earnings came out today.
- Venus Concept VERO shares rose 16.98% to $0.39. The company's market cap stands at $2.8 million. As per the news, the Q3 earnings report came out yesterday.
- FibroBiologics FBLG stock increased by 16.23% to $3.58. The company's market cap stands at $126.2 million. As per the news, the Q3 earnings report came out 2 days ago.
- Adial Pharmaceuticals ADIL stock increased by 13.01% to $1.12. The company's market cap stands at $7.1 million. The company's, Q3 earnings came out yesterday.
- Astria Therapeutics ATXS shares increased by 11.96% to $11.88. The company's market cap stands at $670.3 million. The company's, Q3 earnings came out yesterday.
Losers
- Nuvectis Pharma NVCT shares fell 52.4% to $5.08 during Thursday's pre-market session. The company's market cap stands at $98.1 million.
- icad ICAD stock fell 23.08% to $1.8. The company's market cap stands at $47.4 million. The company's, Q3 earnings came out yesterday.
- OptimizeRx OPRX stock fell 22.77% to $4.75. The company's market cap stands at $87.0 million. The company's, Q3 earnings came out yesterday.
- PDS Biotechnology PDSB shares fell 19.79% to $2.21. The company's market cap stands at $81.3 million. The company's, Q3 earnings came out today.
- Harrow HROW shares decreased by 18.92% to $42.0. The company's market cap stands at $1.4 billion. As per the press release, Q3 earnings came out yesterday.
- Calidi Biotherapeutics CLDI shares decreased by 17.76% to $2.78. The market value of their outstanding shares is at $32.4 million. As per the press release, Q3 earnings came out 2 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in